(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Protagonist Therapeutics (PTGX) has an average rating of outperform and price targets ranging from $21 to $50, according to analysts polled by Capital IQ....
Protagonist Therapeutics (PTGX) has an average rating of buy and price targets ranging from $30 to $60, according to analysts polled by Capital IQ. (MT...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Protagonist Therapeutics (PTGX) shares slumped 53% by Tuesday afternoon, a day after the biopharmaceutical company said a phase 2 study of its proposed...
Protagonist Therapeutics (PTGX) shares slumped 49% amid heavy trading after the company reported topline data from a phase 2 trial of PN-943 in ulcerative...
Protagonist Therapeutics (PTGX) shares slumped 33% after the company reported topline data from a phase 2 trial of PN-943 in ulcerative colitis. InMed...
Health care stocks were narrowly lower this afternoon, with the NYSE Health Care Index slipping 0.1% and the SPDR Health Care Select Sector ETF (XLV) down...
Protagonist Therapeutics (PTGX) said it received a letter from the Food and Drug Administration indicating the regulator's intention to rescind...
(Updates with the stock move in the second paragraph and headline.) Protagonist Therapeutics (PTGX) said late on Wednesday it received a letter from the...